Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 10, 2026

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

EGFR mutation detection by microfluidic technology: a validation study.

Umberto Malapelle¹, Stefania Russo, Francesco Pepe

¹Dipartimento di Sanità Pubblica, Università di Napoli Federico II, , Napoli, Italia.

Journal of Clinical Pathology

|June 25, 2013

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026

Same author

Supernatant: What's in a name?

Cancer cytopathology·2026

Same author

Advances in early-stage lung cancer patients: from preanalytics to molecular analysis.

Critical reviews in oncology/hematology·2026

Same author

Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Same author

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.

Pathologica·2026

Same author

Sepsis in the Emergency Department: Different Faces, Same Fate? A Sex-Based Prognostic Analysis.

International journal of molecular sciences·2026

Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026

Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026

Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026

Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026

Same journal

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026

Same journal

Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.

Journal of clinical pathology·2026

See all related articles

A new microfluidic chip technology offers a faster, more sensitive method for detecting epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer. This approach improves upon traditional sequencing for EGFR testing.

Area of Science:

Oncology
Molecular Biology
Biotechnology

Background:

Advanced non-small cell lung cancer (NSCLC) diagnosis relies on identifying epidermal growth factor receptor (EGFR) gene mutations.
Conventional methods like direct sequencing for EGFR mutation detection are time-consuming and less sensitive.
Fragment length analysis using fluorescently labeled PCR products is an alternative but requires specialized equipment.

Purpose of the Study:

To validate a novel, rapid, and sensitive chip-based microfluidic technology for EGFR mutation detection in NSCLC.
To overcome the limitations of labeled primers and automated capillary electrophoresis.
To establish a cost-effective and efficient diagnostic tool for EGFR mutations.

Main Methods:

Development and validation of a chip-based microfluidic device for fragment length analysis.

Keywords:

EGFR LUNG MOLECULAR PATHOLOGY

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Related Experiment Videos

Last Updated: May 10, 2026

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Comparison of the microfluidic technology's limit of detection (LOD) against direct sequencing.

Quantification of mutated alleles (mA%) using PCR product subcloning and correlation analysis with microfluidic results.

Main Results:

The microfluidic device achieved a limit of detection of 5% for EGFR mutations, significantly more sensitive than direct sequencing (12.5%).
High accuracy was demonstrated in analyzing samples with known mutational status.
Strong correlation (R²=0.9 for both exon 19 and 21) was observed between the microfluidic technology and direct sequencing of subcloned PCR products for quantifying mutated alleles.

Conclusions:

Chip-based microfluidic electrophoresis provides a rapid, sensitive, and cost-effective method for EGFR testing in NSCLC.
This technology offers a significant improvement over existing methods for EGFR mutation analysis.
The validated microfluidic approach has the potential to enhance clinical diagnostics for NSCLC patients.